MXPA04009123A - Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina. - Google Patents
Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina.Info
- Publication number
- MXPA04009123A MXPA04009123A MXPA04009123A MXPA04009123A MXPA04009123A MX PA04009123 A MXPA04009123 A MX PA04009123A MX PA04009123 A MXPA04009123 A MX PA04009123A MX PA04009123 A MXPA04009123 A MX PA04009123A MX PA04009123 A MXPA04009123 A MX PA04009123A
- Authority
- MX
- Mexico
- Prior art keywords
- serotonin
- catecholamine
- precursor
- amino acid
- techonology
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 6
- 150000003943 catecholamines Chemical class 0.000 title abstract 3
- 229940076279 serotonin Drugs 0.000 title abstract 3
- 238000005457 optimization Methods 0.000 title 1
- 239000002243 precursor Substances 0.000 abstract 5
- 229940024606 amino acid Drugs 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical group C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 235000001465 calcium Nutrition 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960001682 n-acetyltyrosine Drugs 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un metodo para tratar disfuncion de neurotransmisor en un paciente. El metodo incluye la etapa de administrar un aminoacido precursor de una catecolamina en un intervalo equilibrado y terapeutico eficaz. El precursor de catecolamina preferiblemente es L-dopa, pero de manera alternativa puede ser tirosina, D- L-fenilalanina o un isomero activo del mismo y N-acetil-L-tirosina u otro aminoacido precursor de L-dopa. Tambien se administra un aminoacido precursor de serotonina en un intervalo terapeuticamente eficaz. El precursor de serotonina preferiblemente es 5-HTP, pero de manera alternativa puede ser triptofano. De manera preferible tambien se administra por lo menos un cofactor. Las opciones de cofactor incluyen vitamina B6, vitamina C, calcio, folato y cisteina. Tambien se describe un metodo de administracion periodica y verificacion del paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36698302P | 2002-03-21 | 2002-03-21 | |
PCT/US2003/008843 WO2003079886A2 (en) | 2002-03-21 | 2003-03-21 | Serotonin and catecholamine system segment optimization techonology |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04009123A true MXPA04009123A (es) | 2005-09-08 |
Family
ID=28454829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04009123A MXPA04009123A (es) | 2002-03-21 | 2003-03-21 | Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina. |
Country Status (7)
Country | Link |
---|---|
US (3) | US20030181509A1 (es) |
EP (1) | EP1490073A4 (es) |
AU (1) | AU2003222045A1 (es) |
BR (1) | BR0308556A (es) |
CA (1) | CA2479218A1 (es) |
MX (1) | MXPA04009123A (es) |
WO (1) | WO2003079886A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
BR0308556A (pt) * | 2002-03-21 | 2005-05-03 | Martin C Hinnz | Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
AU2003903826A0 (en) * | 2003-07-24 | 2003-08-07 | University Of South Australia | An ofdm receiver structure |
MXPA05008943A (es) * | 2003-02-21 | 2005-11-08 | C Hinz Martin | Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina. |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
JP4638685B2 (ja) * | 2003-06-10 | 2011-02-23 | ハイデルベルガー ドルツクマシーネン アクチエンゲゼルシヤフト | オフセット印刷機による印刷の際に湿し水を調量する方法 |
US20070010584A1 (en) * | 2003-09-04 | 2007-01-11 | Peroutka Stephen J | Compositions and methods for orthostatic intolerance |
US20060030625A1 (en) * | 2004-08-06 | 2006-02-09 | Cheryle Ram Hart | Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters |
US20070213370A1 (en) * | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
EP1948155B1 (en) * | 2006-06-28 | 2012-03-07 | Chelsea Therapeutics Inc. | Pharmaceutical compositions comprising droxidopa |
NZ579368A (en) * | 2007-03-09 | 2012-03-30 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
EP2142185B1 (en) * | 2007-03-12 | 2012-08-15 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
ES2431570T3 (es) * | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
WO2012004585A1 (en) * | 2010-07-09 | 2012-01-12 | Abdulla Badawy | Ingestible formulation comprising glycomacropeptide and at least one of tryptophan, tyrosine and phenylalanine and uses thereof |
EP2667711A4 (en) * | 2011-01-26 | 2014-11-12 | Nico Worldwide Inc | MEANS FOR THE TREATMENT OF MIGRAINE |
JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状(姿勢反射異常)の治療剤 |
EP2737809A1 (de) * | 2012-12-03 | 2014-06-04 | MüMed | Aminosäurehaltiges Getränk, geeignet zur Verwendung in der Prophylaxe und Behandlung von psychischen Störungen |
US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3097947A (en) * | 1961-01-30 | 1963-07-16 | Mend Johnson & Company | Nutritional composition and process |
US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
US4237118A (en) * | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
US4397866A (en) * | 1979-05-07 | 1983-08-09 | Massachusetts Institute Of Technology | Process for increasing glycine levels in the brain and spinal cord |
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
US4446138A (en) * | 1982-02-10 | 1984-05-01 | Pack Howard M | Method and composition for reducing weight |
JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
US4596807A (en) * | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5011608A (en) * | 1988-11-18 | 1991-04-30 | Dragana Damjanovic | Biogenic amine assay using HPLC-ECD |
US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
US5019594A (en) * | 1989-11-28 | 1991-05-28 | Interneuron Pharmaceuticals, Inc. | Method for decreasing appetite |
EP0533818B1 (en) * | 1990-06-13 | 1997-12-17 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Process for activating reproduction of seasonal breeding animals by administering l-dihydroxyphenylalanine (l-dopa) |
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
US5480657A (en) * | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
WO1996003989A1 (fr) * | 1994-08-05 | 1996-02-15 | Suntory Limited | Remede contre la degenerescence spino-cerebelleuse |
US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
ES2184111T3 (es) * | 1996-07-05 | 2003-04-01 | Wwk Trust | Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor. |
US20010020007A1 (en) * | 1996-08-26 | 2001-09-06 | Oswald Wiss | Vitamin preparations for reducing oxygen consumption during physical efforts |
GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
US5977076A (en) * | 1997-04-14 | 1999-11-02 | Anderson; Byron E. | Method and material for inhibiting complement |
US20010002269A1 (en) * | 1997-05-06 | 2001-05-31 | Zhao Iris Ginron | Multi-phase food & beverage |
US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
US5939076A (en) * | 1997-11-12 | 1999-08-17 | Allocca Techical, Inc. | Composition and method for treating or alleviating migraine headaches |
US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
DK1158973T3 (da) * | 1999-02-24 | 2005-05-30 | Univ Cincinnati | Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser |
US6261589B1 (en) * | 1999-03-02 | 2001-07-17 | Durk Pearson | Dietary supplement nutrient soft drink composition with psychoactive effect |
US6123724A (en) * | 1999-04-14 | 2000-09-26 | Denker; Stephen | Heart assist method and apparatus employing magnetic repulsion force |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6955873B1 (en) * | 2000-08-04 | 2005-10-18 | Kenneth Blum | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors |
DE29923436U1 (de) * | 1999-09-18 | 2000-09-07 | Utility Consult Hinzmann & König OHG, 20249 Hamburg | Verbrauchszähler für flüssige und gasförmige Medien |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
AU8003800A (en) * | 1999-10-08 | 2001-04-23 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
US20020147206A1 (en) * | 2001-04-05 | 2002-10-10 | Pfizer Inc. | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |
US20060014773A1 (en) * | 2001-04-19 | 2006-01-19 | Mccleary Edward L | Mental agility lozenge, edible strip, food or drink |
US6541043B2 (en) * | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
US8142799B2 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | High potency clinical anti-craving treatment and method of use |
US20060110325A1 (en) * | 2003-02-21 | 2006-05-25 | Hinz Martin C | Serotonin and catecholamine segment optimization technology |
BR0308556A (pt) * | 2002-03-21 | 2005-05-03 | Martin C Hinnz | Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas |
US20040077556A1 (en) * | 2002-04-22 | 2004-04-22 | Robert Chinery | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US20040071681A1 (en) * | 2002-10-10 | 2004-04-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
US20040116351A1 (en) * | 2002-12-06 | 2004-06-17 | Fast Balance, Inc. | Method for enhancing the natural reward system for exercise |
US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
MXPA05008943A (es) * | 2003-02-21 | 2005-11-08 | C Hinz Martin | Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina. |
US20050233014A1 (en) * | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for affecting homeostasis and metabolism in a mammalian body |
US20060062859A1 (en) * | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
-
2003
- 2003-03-21 BR BR0308556-2A patent/BR0308556A/pt not_active IP Right Cessation
- 2003-03-21 WO PCT/US2003/008843 patent/WO2003079886A2/en not_active Application Discontinuation
- 2003-03-21 US US10/394,597 patent/US20030181509A1/en not_active Abandoned
- 2003-03-21 EP EP03718029A patent/EP1490073A4/en not_active Withdrawn
- 2003-03-21 AU AU2003222045A patent/AU2003222045A1/en not_active Abandoned
- 2003-03-21 CA CA002479218A patent/CA2479218A1/en not_active Abandoned
- 2003-03-21 MX MXPA04009123A patent/MXPA04009123A/es unknown
-
2006
- 2006-02-14 US US11/353,644 patent/US20060178423A1/en not_active Abandoned
-
2008
- 2008-03-28 US US12/058,338 patent/US20080241278A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0308556A (pt) | 2005-05-03 |
US20030181509A1 (en) | 2003-09-25 |
EP1490073A4 (en) | 2006-02-01 |
WO2003079886A3 (en) | 2004-02-12 |
US20060178423A1 (en) | 2006-08-10 |
AU2003222045A1 (en) | 2003-10-08 |
US20080241278A1 (en) | 2008-10-02 |
CA2479218A1 (en) | 2003-10-02 |
AU2003222045A8 (en) | 2003-10-08 |
WO2003079886A2 (en) | 2003-10-02 |
EP1490073A2 (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04009123A (es) | Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina. | |
Chen et al. | Pharmacotherapy for Parkinson's disease | |
Tuite et al. | Recent developments in the pharmacological treatment of Parkinson’s disease | |
US20130064804A1 (en) | BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE | |
HRP20050077B1 (hr) | Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona | |
WO2003063876A3 (en) | Methods of treating patients suffering from movement disorders | |
CA2566384A1 (en) | Oral therapeutic compound delivery system | |
US20160082006A1 (en) | Pharmacological treatment of parkinson's disease | |
TW200738228A (en) | Neramexane modified release matrix tablet | |
NO339404B1 (no) | Farmasøytisk formulering med apomorfin for bukkal administrering | |
MXPA05008943A (es) | Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina. | |
WO2006037061A3 (en) | Compositions and methods of using d-dopa to treat parkinson's disease | |
MX2022008342A (es) | Metodos para tratar afecciones relacionadas con el receptor de s1p1. | |
HK1086548A1 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
CN101022795B (zh) | L-色氨酸与卡比多巴/苄丝肼的制剂 | |
Suchowersky | Parkinson’s disease: medical treatment of moderate to advanced disease | |
WO1989003211A1 (en) | Treatment of cocaine addiction | |
US20010034320A1 (en) | NK1-receptor antagonists for treating restless legs syndrome | |
JP4812394B2 (ja) | 鎮痛用組成物 | |
WO2006014507A3 (en) | Method for inhibiting lipid peroxidation | |
Shimizu et al. | Delayed L-DOPA-induced hyperalgesia | |
Vo et al. | Guidelines for the Use of Parkinsonian Drugs (in USA) | |
Kanthed et al. | A Pain Physician’s Perspective on Recent Advances in Painful Diabetic Peripheral Neuropathy Management | |
Dickey et al. | 04118 Results of the AURORA study: a phase 2, randomized, double-blind, placebo-controlled study of bitopertin in erythropoietic protoporphyria | |
US6967206B2 (en) | Compositions and methods for increasing growth hormone levels |